Eli Lilly (LLY) -5.1% after saying it will carry out another Phase III trial of its solanezumab...
Wednesday, December 12, 2012, 8:08 AM ETEli Lilly (LLY) -5.1% after saying it will carry out another Phase III trial of its solanezumab treatment in patients with mild symptoms of Alzheimer's disease, and will delay applying for approval in the U.S. and Europe following meetings with regulators. The postponement is unlikely to surprise SA author Brian Wilson, who pointed out that apparent patient improvement in two previous studies was "not statistically significant." (PR)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles